Published in AIDS Weekly, April 12th, 2004
"A 14-day open-label, phase 1/2 dose-escalation monotherapy study of the safety and antiretroviral activity of T-1249 was performed on 115 HIV-1-infected adults," by J.J. Eron and coauthors working with Trimeris, Inc. in Durham.
"At baseline, the majority of the patients had advanced HIV disease (baseline median CD4+ cell count, 57 cells/mcL) and had extensive...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.